{"product_id":"ipamorelin-copy","title":"TIRZEPATIDE (40mg)","description":"\u003cp class=\"MsoNormal\" style=\"margin-bottom: 9.0pt;\"\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eTirzepatide is a dual GIP\/GLP-1 receptor agonist representing a significant advance over single-receptor GLP-1 therapies. This 40mg presentation provides a high-volume option for extended research protocols or studies requiring multi-week compound supply without frequent reconstitution. Clinical trials have consistently demonstrated superior body weight reduction outcomes compared to all approved GLP-1 monotherapies.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" style=\"margin: 6.0pt 0in 5.0pt 0in;\"\u003e\u003cb\u003e\u003cspan style=\"font-size: 12.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial; color: #2e6da4;\"\u003eMechanism of Action\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e        \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eDual GLP-1 and GIP receptor agonism produces synergistic appetite suppression and metabolic improvement in research models.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e        \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eStudied for reductions in postprandial glucose through insulin secretion potentiation and glucagon suppression.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e        \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eResearch shows slowed gastric emptying to prolong satiety signals and improve caloric balance.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e        \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eInvestigated for beta-cell function preservation in type 2 diabetes models.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" style=\"margin: 7.0pt 0in 5.0pt 0in;\"\u003e\u003cb\u003e\u003cspan style=\"font-size: 12.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial; color: #2e6da4;\"\u003eResearch Areas\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e        \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eExtended obesity and overweight pharmacology research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e        \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eType 2 diabetes with significant overweight component studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e        \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eCardiovascular risk factor reduction through weight and glycemic biology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e        \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eMulti-week supply protocols for longitudinal metabolic research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" style=\"margin: 7.0pt 0in 4.0pt 0in;\"\u003e\u003cb\u003e\u003cspan style=\"font-size: 12.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial; color: #2e6da4;\"\u003ePresentation and Storage\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" style=\"margin-bottom: 3.0pt;\"\u003e\u003ci\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial; color: #444444;\"\u003eSupplied as a lyophilized powder in a sealed vial containing 40mg of tirzepatide. Reconstitute with bacteriostatic water for laboratory use. Store at -20C.\u003c\/span\u003e\u003c\/i\u003e\u003c\/p\u003e","brand":"bioreverselabs.com","offers":[{"title":"Default Title","offer_id":45880856412333,"sku":null,"price":6600.0,"currency_code":"MXN","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0761\/1577\/1565\/files\/34.png?v=1775136935","url":"https:\/\/bioreverselabs.com\/products\/ipamorelin-copy","provider":"Bio Reverse Labs","version":"1.0","type":"link"}